OMERS ADMINISTRATION Corp Sells 54,036 Shares of Hologic, Inc. (NASDAQ:HOLX)

OMERS ADMINISTRATION Corp cut its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 38.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,178 shares of the medical equipment provider's stock after selling 54,036 shares during the period. OMERS ADMINISTRATION Corp's holdings in Hologic were worth $6,213,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Hologic by 2.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,256 shares of the medical equipment provider's stock valued at $2,542,000 after purchasing an additional 869 shares during the period. Lighthouse Investment Partners LLC purchased a new stake in shares of Hologic during the 4th quarter worth about $1,081,000. Jefferies Financial Group Inc. lifted its stake in Hologic by 141.5% in the 4th quarter. Jefferies Financial Group Inc. now owns 96,849 shares of the medical equipment provider's stock valued at $6,982,000 after buying an additional 56,742 shares in the last quarter. Kahn Brothers Group Inc. boosted its holdings in shares of Hologic by 15.6% during the 4th quarter. Kahn Brothers Group Inc. now owns 29,591 shares of the medical equipment provider's stock worth $2,134,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Humankind Investments LLC raised its position in shares of Hologic by 8.3% during the 4th quarter. Humankind Investments LLC now owns 5,453 shares of the medical equipment provider's stock valued at $393,000 after buying an additional 418 shares during the period. Institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on HOLX. Raymond James reaffirmed an "outperform" rating and issued a $71.00 price target (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a report on Friday, May 2nd. Royal Bank of Canada decreased their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Morgan Stanley lowered their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $77.42.

Insider Activity at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.88% of the company's stock.

Hologic Price Performance

Shares of NASDAQ:HOLX traded down $0.50 during midday trading on Monday, hitting $56.30. The company's stock had a trading volume of 351,347 shares, compared to its average volume of 2,119,634. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The company has a market cap of $12.55 billion, a P/E ratio of 17.76, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The business's 50 day simple moving average is $58.76 and its 200 day simple moving average is $67.32. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Hologic's revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.03 EPS. On average, analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.